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Abstract
Background: In the last decade many studies have definitely shown that human papillomaviruses
(HPVs) are the major cause of cervical carcinogenesis and, in the last few years, HPV testing has
been proposed as a new and more powerful tool for cervical cancer screening. This issue is now
receiving considerable attention in scientific and non scientific press and HPV testing could be
considered the most important change in this field since the introduction of cervical cytology. This
paper reports our prevalence data of HPV infection collected in the '90s, while a follow up of these
patients is ongoing.
Methods: For this study we used polymerase chain reaction (PCR) to search HPV DNA sequences
in cervical cell scrapings obtained from 503 asymptomatic women attending regular cervical cancer
screening program in the city of Genova, Italy. All patients were also submitted to a self-
administered, standardized, questionnaire regarding their life style and sexual activity. On the basis
of the presence of HPV DNA sequences women were separated into two groups: "infected" and
"non infected" and a statistical analysis of the factors potentially associated with the infection group
membership was carried out.
Results: The infection rate was 15.9% and the most frequent viral type was HPV 16.
Conclusion: Our HPV positivity rate (15.9%) was consistent to that reported by other studies on
European populations.
Background
Although the Pap-test has given a great contribution to
early diagnosis of cervical cancer, this is still a very com-
mon, worldwide distributed, female neoplasm and a
major cause of death in developing countries. Moreover,
in developed countries, the treatment of preneoplastic cer-
vical lesions is a considerable public health problem.
There is now strong evidence that infection with
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carcinogenic types of HPV represents a nearly universal
event in cervical carcinoma development and sexual trans-
mission is the predominant mode of HPV infection [1-3].
The relative risk of cervical cancer associated with high-
risk types of HPV is even higher than the risk of lung can-
cer associated with smoking. More than 50 HPV types
infecting the genital tract have been identified and
sequenced and they can be associated with distinct clini-
cal manifestation. Some HPV types, like 6 and 11, are
cause of benign condylomas (low risk group) while a
wider number of subtypes (HPV 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68) has been proved to be involved in
cervical carcinogenesis (high risk group). Several onco-
genes have been identified in the oncogenic types and the
biologic mechanism of malignant transformation has
been increasingly well characterized [4].
HPV testing for cancer-associated HPV DNA is now
accepted as a viable and validated option in the manage-
ment of women with equivocal cytologic findings [5-7]
and, in the last few years, there has been an increasing
interest in using the HPV testing also in cervical samples
from asymptomatic women without cytological abnor-
malities [8-10]. This strategy seems to allow an early iden-
tification of populations at different risk level for this
neoplasia because the absence of infection makes the risk
of cancer negligible. Large-scale screening studies demon-
strated that HPV testing is more sensitive for the detection
of high-grade cervical lesions than cytology.
Nevertheless, the lower specificity and the high cost of
HPV testing make its use in primary cervical cancer screen-
ing still questionable. At the same time very promising tri-
als are ongoing to evaluate the efficacy of prophylactic
HPV 16 vaccines [11,12]. These results suggest that the
increasing knowledge about the importance of HPV infec-
tion is probably leading to new prevention strategies for
this disease. Polymerase Chain Reaction (PCR) is a sensi-
tive technique for the detection of very small amounts of
HPV's nucleic acids in clinical specimens and it has been
used in most epidemiological studies that have evaluated
the role of these viruses in cervical cancer causation. In the
'90s we performed a study of prevalence of this infection
in cervical samples obtained from women attending their
annual screening. This paper presents our historical data
and, in our knowledge, this is the first report regarding an
Italian population.
Methods
This study included 514 women attending the Istituto
Nazionale per la Ricerca sul Cancro in Genova (Italy) for
their routine annual Pap smear from June 1992 to June
1993. At the time of their visit all the participants were
informed of the research and its purpose and gave their
informed consent. Then, they were invited to fill in a self
administered questionnaire including items about life-
time number of male sexual partners, age at first inter-
course, history of pregnancy and sexually transmitted
diseases, contraceptives methods, smoking, prior abnor-
mal Pap smears and other variables. Pap smears were all
reviewed by the same pathologist according to the
Bethesda System 1991 (figure 1) [13], without knowledge
of clinical or laboratory data.
Sample preparation
Cervical specimens were collected with a cotton swab pre-
wet with PBS and suspended in a 50 ml conical tube con-
taining 10 ml PBS. The tube was vortexed to remove all
the material from the swab, which was discarded. The
tube was then centrifuged at 2000 g for 10 min, the super-
natant was removed and discarded, the pellet resus-
pended in 500 µl PBS, transferred into a 1.5 ml Eppendorf
tube and frozen at -80°C until DNA extraction was per-
formed with the following procedure: phenol/chloro-
phorm:isoamyl alcohol 24:1, precipitation with 0.3 M
sodium acetate in 2.5 V/V pure ethanol, centrifugation at
14,000 rpm for 20 min, washing with 70% ethanol, resus-
pension in double distilled water.
Bethesda System 1991 Figure 1
Bethesda System 1991.
SPECIMEN ADEQUACY
o Satisfactory for evaluation
o Unsatisfactory for evaluation (specify)
GENERAL CATEGORIZATION (optional)
o Negative for SIL or malignancy
o Benignant cellular changes
o Epithelial cells abnormalities
DESCRIPTIVE DIAGNOSIS
o Benignant cellular changes
  Infections
  Reactive changes
o Epithelial cells abnormalities
  Squamous cells
• ASCUS
• L-SIL/HPV
• H-SIL
• Squamous cells carcinoma
  Glandular cells
• Endometrial cells, cytologically benign, in a postmenopausal woman
• AGUS
• Endocervical adenocarcinoma
• Endometrial adenocarcinoma
• Extrauterine adenocarcinoma
• Adenocarcinoma NOS
  Other malignant neoplasms (specify)BMC Infectious Diseases 2005, 5:77 http://www.biomedcentral.com/1471-2334/5/77
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PCR
The consensus primers MY09 and MY11 were used for the
amplification in the following 100 µl reaction mixture: 10
µl of 10 × PCR buffer, 0.2 µM of each primer, 200 µM of
each dNTP, 2.5 units of Taq polymerase (Perkin Elmer/
Cetus), 200 ng of sample DNA, double distilled water.
The apmplification was performed in a DNA Thermal
Cycler (Perkin Elmer/Cetus Instruments), using the fol-
lowing program set: 95°C for 30 sec., 55°C for 30 sec.,
72°C for 1 min. for a total number of 30 cycles plus an
additional 9 min. at 72°C. Separate rooms were used for:
preparation of DNA template, preparation and storage of
reagents, setting up the amplification reaction. All rea-
gents used in PCR were prepared, aliquotted and stored in
an area that was free of PCR- amplified products. Amplifi-
cation of a single copy human gene (β-globin), as control
Table 1: Distribution of selected characteristics observed in the 503 patients included in the study.
N° 503
Age Mean (s.d.) 51 (12.3)
Range 20–81
Age at first intercourse Mean (s.d.) 20.8 (6.3)
Range 5*-38
Marital status Single 123 (24.45%)
Married 369 (73.36%)
Unknown 11 (2.19%)
Education High school or University 207 (41.1%)
Middle School 167 (33.2%)
Primary School 120 (23.8%)
Unknown 9( 1 . 9 % )
History of pregnancy 0 90 (17.8%)
1–2 263 (52.2%)
≥ 3 137 (27.2%)
n.a. 13 (2.5%)
N° of lifetime partners 1 294 (58.45%)
2–4 74 (14.71%)
5–9 33 (6.56%)
≥ 10 47 (9.34%)
Unknown 55 (10.93%)
History of sexually transmitted diseases No 479 (95.2%)
Yes 24 (4.8%)
Smoking No 348 (69.2%)
Yes 155 (30.8%)
Oral contraceptives No 337 (67%)
Yes/ex 166 (33%)
History of abnormal Pap-smear 50/503 (9.94%)
SIL in the present Pap smear 3/503 (0.6%)
* sexual abuse
Table 2: Viral type distribution by age group assessed by PCR and dot-blot analyses. The percentage of PCR and dot-blot positive 
samples (among HPV-PCR +) are shown in parenthesis.
PCR analysis Dot-blot analysis
Age HPV (all) Generic probe 6/11 16 18 33 Others
≤ 44 18/119 (15.1%) 16 (88.9%) 1 (5.6%) 8 (44.4%) 4 (22.2%) 2 (11.1%) 2 (11.1%)
45–52 21/120 (17.5%) 19 (90.5%) 2 (9.5%) 10 (47.6%) 11 (52.4%) 3 (14.3%) 2 (9.5%)
53–59 14/122 (11.5%) 13 (92.9%) 0 11 (78.6%) 4 (28.6%) 0 1 (7.1%)
≤ 60 27/142 (19.0%) 26 (96.3%) 1 (3.7%) 17 (63.0%) 10 (37.0%) 2 (7.4%) 2 (7.4%)
All 80/503 (15.9%) 74 (92.5%) 4 (5.0%) 46 (57.5) 29 (36.3) 7 (8.8%) 7 (8.8%)BMC Infectious Diseases 2005, 5:77 http://www.biomedcentral.com/1471-2334/5/77
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of DNA suitability for amplification, was performed in
each reaction tube; we also used He-La cells as positive
control and K562 cells as negative control in each reation.
Analysis of the amplification products
10 µl of the amplification mixture were analysed by elec-
trophoresis in 1.5 agarose gel and visualized by UV light
after ethidium bromide staining. Dot-blot analysis was
then performed using 2 and 5 µl of the PCR mixture after
alkaline denaturation treatment (NaOH 1.5 M and NaCl
0.5 M). DNA was transferred onto nylon membranes
Hybond N+ (Amersham, UK) using the Dot-blot appara-
tus (Millipore, USA) under constant vacuum conditions.
Replicate membranes were used for Hybridization with
each of the type specific probes (MY12, MY13, MY14,
WD74 and MY16) and the generic probe mix (GP1 and
GP2). For detection we used the ECL chemoillumines-
cence kit (Amersham, UK).
Statistical analysis
The associations between HPV infection (defined as a pos-
itive HPV-PCR) and individual covariates, including age,
age at first sexual intercourse, marital status, smoking hab-
its, education, number of lifetime partners and use of oral
contraceptives was investigated using univariate and mul-
tiple logistic regression (MLR) analyses. The analyses were
done with the SPSS Statistical Software (SPSS Inc. Chicago
Illinois). Odds ratios point estimates (OR) and their 95%
confidence intervals (95% CIs) were computed by MLR
procedure for binary data to estimate the association
between each covariate levels and HPV infections while
adjusting for the effect of other variables retained in the
model. Statistical tests were considered to be significant if
the p value was 0.05 or less.
Results
Amongst 514 women enrolled in this study, 503 samples
were adequate for PCR. The most important patient char-
acteristics are shown in table 1. The mean age was 51 years
(SD = 12.3). Our group was heterogeneous for schooling
and other socio-economic variables. Three out of 503
women had cytological abnormal findings (SIL) and no
one had genital warts on examination at enrollment. As
shown in table 2, 80/503 (15.9%) samples were found
positive for HPV infection. The distribution of different
viral types by age group is shown in table 2. HPV 16 was
the most frequently found subtype (46/80, 57.5%). 19/80
(23.7%) samples were positive for more than one type.
Patients carrying a SIL (3/503) were all found positive for
HPV (2 for type 16; 1 for type 18+33). The results of the
univariate and multiple logistic regression analyses are
shown in table 3 and 4, respectively. The number of male
lifetime partners was the only covariate significantly asso-
ciated with HPV infection in univariate analysis (p =
Table 3: Findings from the univariate analysis: HPV positive patients by selected covariates
Covariates All Women HPV Positive P value χ2 test
No. No. %
Age ≤ 44 119 18 15.1 0.37
45–52 120 21 17.5
53–59 122 14 11.5
≥ 60 142 27 19.0
Education Primary School 120 12 10.0 0.09
Secondary School 167 27 16.2
Higher 207 40 19.3
Unknown 9 - -
Smoking habits Current + previous 155 26 16.8 0.79
Never smokers 348 54 15.5
N° of lifetime partners 1 293 35 11.9 0.03
> 1 ≤ 57 4 1 3 1 7 . 6
> 5 78 19 24.4
Unknown 58 12 20.0
Age at 1° sexual intercourse ≤ 18 128 22 17.2 0.63
19 – 21 138 24 17.4
22 – 24 109 13 11.9
≥ 24 125 19 15.2
Marital status Single 123 27 21.95 0.06
Married 369 52 14.1
Unknown 11 - -
Use of Oral Contraceptives Current + previous 166 27 16.3 0.88
Never 337 53 15.7BMC Infectious Diseases 2005, 5:77 http://www.biomedcentral.com/1471-2334/5/77
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0.03). In multiple regression analysis increased ORs were
found to be associated with higher levels of education (p
trend = 0.03) while none of the other covariates, includ-
ing the number of male lifetime partners, was associated
with HPV infection.
Discussion
In the nineteenth century some investigators noticed that
cervical cancer was almost exclusively detected in married
women, being rare in the unmarried ones and exceptional
in nuns [20,21]. Since then, a large number of studies
have investigated the importance of sexual activity as the
main risk factor for cervical carcinoma development
(increased risk related to early onset and number of
lifetime partners), suggesting a role for a sexually trans-
mitted infectious agent. More recently, many epidemio-
logical studies have identified HPV as the main factor in
cervical cancer causation [14,22]. At the time of this study
we wanted to investigate whether there was any associa-
tion between genital HPV infection and known risk fac-
tors for cervical cancer. The sample we studied was a non
selected population attending our hospital from the
whole Liguria Region, in Italy. Our HPV positivity rate
(15.9%) was low compared to that detected by the first
studies conducted using PCR [14,23], but it matches well
with prevalence data more recently detected in other
European countries [8,15,24,25]. A significant relation-
ship was observed in our population between age and
HPV infection. Moreover, in the group aged ≤ 30 (33
women) the HPV prevalence was higher (27.3% vs 15.1%,
data not shown) and similar to that reported by other
investigators [14-19]. The different HPV frequency
between age groups could be due to their different sexual
behaviour, although this cannot completely explain the
findings of the intermediate age group (>30 y.o., <50
y.o.). In fact the sexual habits of this population, as con-
firmed by the questionnaires, are similar to those of
younger subjects (<30 y.o.), but HPV is detectable in a
lower rate (16%), close to the value found for the older
group. A better explanation of these results, also reported
by other studies [18,26], is that most HPV genital infec-
tions are transient because they are cleared by host
immune response. In fact serum IgG antibodies develop
in response to infection in 55–92% of women [12,27].
These data are very helpful now that the introduction of
HPV testing in cervical cancer screening seems to be
Table 4: Findings from multiple logistic regression: Odds Ratios (OR) point estimates and their 95% Confidence Intervals (95% C.I.)
Covariate No. OR (a) 95% C.I. P (b) P trend(c)
Age
≤ 44 106 1 (ref.) 0.21 0.13
45 – 52 113 1.88 0.80 – 4.41
53 – 59 103 1.20 0.45 – 3.18
≥ 60 110 2.29 0.89 – 5.89
No. of lifetime partners
1 283 1 (ref.) 0.29 0.11
1 – 5 71 1.30 0.61 – 2.78
> 5 78 1.82 0.86 – 3.85
Use of Oral Contraceptives.
No 284 1 (ref.) 0.64
Yes 148 1.16 0.61 – 2.21
Education
Primary 93 1 (ref.) 0.44 0.03
Secondary 153 1.39 0.61 – 3.16
Higher 186 1.72 0.73 – 4.03
Smoking
No 290 1 (ref.) 0.92
Yes 142 0.97 0.54 – 1.74
Age 1° intercourse
≤ 18 94 1 (ref.) 0.74 0.63
19 – 21 124 1.04 0.48 – 2.24
22 – 24 100 0.70 0.28 – 1.70
> 24 114 0.77 0.32 – 1.86
Marital status
Single 101 1 (ref.) 0.31
Married 331 0.71 0.37 – 1.36
The analysis is based on 432 women with complete data; all variables included in the model. (a) (ref.) = reference level; (b) Wald test for the 
contribution of the covariate to the logistic model; (c) Test for linear trend within individual categorical covariates.BMC Infectious Diseases 2005, 5:77 http://www.biomedcentral.com/1471-2334/5/77
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incoming, and new guidelines are needed. Our data sup-
port the evidence that this kind of screening should not
start before age 30 (later in comparison to the cytology –
based screening), because in young women HPV infection
is too frequent [8,19,24].
In our population the "higher education" was the most
represented group (205/436 subjects), and this may have
affected the observed association with HPV infection, due
to a an easier access to health system services.
According to other studies, the most frequent viral type
was HPV 16 [15], an important finding when planning
new prevention strategies (e.g. prophylactic vaccines).
Smoking and use of oral contraceptives, previously
reported to be risk factors for cervical carcinoma develop-
ment, were not related to HPV infection in our data. A
major confounding factor of the present investigation is
the lack of objective and anamnestic data regarding male
partners. Moreover other factors (such as the immune
response to the HPV) still need to be better evaluated.
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